Last reviewed · How we verify

Tesomet "Low dose" in fasted condition

Saniona · FDA-approved active Small molecule

Tesomet is a combination of tesofensine (a monoamine reuptake inhibitor) and metformin that promotes weight loss by increasing satiety and energy expenditure while improving metabolic control.

Tesomet is a combination of tesofensine (a monoamine reuptake inhibitor) and metformin that promotes weight loss by increasing satiety and energy expenditure while improving metabolic control. Used for Obesity or overweight with comorbidities (marketed in Europe).

At a glance

Generic nameTesomet "Low dose" in fasted condition
Also known asTesofensine, Metoprolol
SponsorSaniona
Drug classMonoamine reuptake inhibitor + biguanide combination
TargetSerotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT); metformin targets mitochondrial glycerophosphate dehydrogenase
ModalitySmall molecule
Therapeutic areaEndocrinology / Obesity
PhaseFDA-approved

Mechanism of action

Tesofensine inhibits the reuptake of serotonin, norepinephrine, and dopamine in the central nervous system, leading to reduced appetite and increased energy expenditure. Metformin improves insulin sensitivity and glucose metabolism. Together, the combination targets both weight reduction and metabolic parameters in obesity management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: